Anti-inflammatory agents design via the fragment hybrid strategy in the discovery of compound c1 for treating ALI and UC.

Fuente: PubMed
Salvato in:
Dettagli Bibliografici
Autori principali: Guo, Mi, Zou, Yu, Dong, Ke, Huang, Nan, Chen, Zhichao, Sun, Chenhui, Chen, Pan, Chen, Qi, Zhu, Luxiao, Lv, Yuehua, Zhang, Kaixin, Jiang, Miao, Gao, Yitian, Cho, Young-Chang, Tang, Qidong, Liang, Guang, Wu, Di
Natura: Artículo científico
Lingua:en
Pubblicazione: European journal of medicinal chemistry 2025
Soggetti:
Accesso online:
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
_version_ 1868266234582138880
author Guo, Mi
Zou, Yu
Dong, Ke
Huang, Nan
Chen, Zhichao
Sun, Chenhui
Chen, Pan
Chen, Qi
Zhu, Luxiao
Lv, Yuehua
Zhang, Kaixin
Jiang, Miao
Gao, Yitian
Cho, Young-Chang
Tang, Qidong
Liang, Guang
Wu, Di
author_facet Guo, Mi
Zou, Yu
Dong, Ke
Huang, Nan
Chen, Zhichao
Sun, Chenhui
Chen, Pan
Chen, Qi
Zhu, Luxiao
Lv, Yuehua
Zhang, Kaixin
Jiang, Miao
Gao, Yitian
Cho, Young-Chang
Tang, Qidong
Liang, Guang
Wu, Di
Guo, Mi
Zou, Yu
Dong, Ke
Huang, Nan
Chen, Zhichao
Sun, Chenhui
Chen, Pan
Chen, Qi
Zhu, Luxiao
Lv, Yuehua
Zhang, Kaixin
Jiang, Miao
Gao, Yitian
Cho, Young-Chang
Tang, Qidong
Liang, Guang
Wu, Di
collection PubMed - marine biology
contents Anti-inflammatory agents design via the fragment hybrid strategy in the discovery of compound c1 for treating ALI and UC. Guo, Mi Zou, Yu Dong, Ke Huang, Nan Chen, Zhichao Sun, Chenhui Chen, Pan Chen, Qi Zhu, Luxiao Lv, Yuehua Zhang, Kaixin Jiang, Miao Gao, Yitian Cho, Young-Chang Tang, Qidong Liang, Guang Wu, Di Animals Mice Humans Acute Lung Injury Colitis, Ulcerative Lipopolysaccharides Drug Design Structure-Activity Relationship Molecular Structure Quinazolines Dose-Response Relationship, Drug Male RAW 264.7 Cells Anti-Inflammatory Agents, Non-Steroidal Drug Discovery Anti-Inflammatory Agents Dextran Sulfate Mice, Inbred C57BL Acute lung injury (ALI) and ulcerative colitis (UC) are common inflammatory diseases with high mortality rates and unsatisfactory cure rates. Studies have indicated that inhibiting the expression and release of inflammatory factors holds potential for the treatment of inflammatory diseases. In this study, we designed and synthesized 28 derivatives of 6,7-disubstituted-4-cis-cyclohexanequinazoline and assessed their anti-inflammatory activities in mouse macrophages RAW264.7, J774A.1, and human monocyte THP-1 cell lines. Among them, derivative c1 was found to significantly inhibit the expression and release of pro-inflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) induced by lipopolysaccharide (LPS) in the three cells mentioned above. It was also demonstrated that c1 could bind to IRAK4 and affect the expression of these two inflammatory factors by inhibiting the activation of the MAPK pathway. Furthermore, in vivo experiments revealed that c1 effectively ameliorated LPS-induced ALI and dextran sulfate sodium (DSS)-induced UC. Additionally, we evaluated the pharmacokinetic properties and in vivo safety of c1. Therefore, our research has identified the 6,7-disubstituted-4-cis-cyclohexanequinazoline derivative c1 exhibiting promising anti-inflammatory effects as a prospective anti-inflammatory drug candidate.
format Artículo científico
id pubmed_40037062
institution PubMed
language en
publishDate 2025
publisher European journal of medicinal chemistry
record_format pubmed
spellingShingle Anti-inflammatory agents design via the fragment hybrid strategy in the discovery of compound c1 for treating ALI and UC.
Guo, Mi
Zou, Yu
Dong, Ke
Huang, Nan
Chen, Zhichao
Sun, Chenhui
Chen, Pan
Chen, Qi
Zhu, Luxiao
Lv, Yuehua
Zhang, Kaixin
Jiang, Miao
Gao, Yitian
Cho, Young-Chang
Tang, Qidong
Liang, Guang
Wu, Di
Animals
Mice
Humans
Acute Lung Injury
Colitis, Ulcerative
Lipopolysaccharides
Drug Design
Structure-Activity Relationship
Molecular Structure
Quinazolines
Dose-Response Relationship, Drug
Male
RAW 264.7 Cells
Anti-Inflammatory Agents, Non-Steroidal
Drug Discovery
Anti-Inflammatory Agents
Dextran Sulfate
Mice, Inbred C57BL
Anti-inflammatory agents design via the fragment hybrid strategy in the discovery of compound c1 for treating ALI and UC. Guo, Mi Zou, Yu Dong, Ke Huang, Nan Chen, Zhichao Sun, Chenhui Chen, Pan Chen, Qi Zhu, Luxiao Lv, Yuehua Zhang, Kaixin Jiang, Miao Gao, Yitian Cho, Young-Chang Tang, Qidong Liang, Guang Wu, Di Animals Mice Humans Acute Lung Injury Colitis, Ulcerative Lipopolysaccharides Drug Design Structure-Activity Relationship Molecular Structure Quinazolines Dose-Response Relationship, Drug Male RAW 264.7 Cells Anti-Inflammatory Agents, Non-Steroidal Drug Discovery Anti-Inflammatory Agents Dextran Sulfate Mice, Inbred C57BL Acute lung injury (ALI) and ulcerative colitis (UC) are common inflammatory diseases with high mortality rates and unsatisfactory cure rates. Studies have indicated that inhibiting the expression and release of inflammatory factors holds potential for the treatment of inflammatory diseases. In this study, we designed and synthesized 28 derivatives of 6,7-disubstituted-4-cis-cyclohexanequinazoline and assessed their anti-inflammatory activities in mouse macrophages RAW264.7, J774A.1, and human monocyte THP-1 cell lines. Among them, derivative c1 was found to significantly inhibit the expression and release of pro-inflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) induced by lipopolysaccharide (LPS) in the three cells mentioned above. It was also demonstrated that c1 could bind to IRAK4 and affect the expression of these two inflammatory factors by inhibiting the activation of the MAPK pathway. Furthermore, in vivo experiments revealed that c1 effectively ameliorated LPS-induced ALI and dextran sulfate sodium (DSS)-induced UC. Additionally, we evaluated the pharmacokinetic properties and in vivo safety of c1. Therefore, our research has identified the 6,7-disubstituted-4-cis-cyclohexanequinazoline derivative c1 exhibiting promising anti-inflammatory effects as a prospective anti-inflammatory drug candidate.
title Anti-inflammatory agents design via the fragment hybrid strategy in the discovery of compound c1 for treating ALI and UC.
topic Animals
Mice
Humans
Acute Lung Injury
Colitis, Ulcerative
Lipopolysaccharides
Drug Design
Structure-Activity Relationship
Molecular Structure
Quinazolines
Dose-Response Relationship, Drug
Male
RAW 264.7 Cells
Anti-Inflammatory Agents, Non-Steroidal
Drug Discovery
Anti-Inflammatory Agents
Dextran Sulfate
Mice, Inbred C57BL
url https://pubmed.ncbi.nlm.nih.gov/40037062/